Carcinoma, Neuroendocrine
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Subtype terms (4)
More specific conditions that are subtypes of Carcinoma, Neuroendocrine in the MeSH hierarchy.
- Carcinoma, Medullary
4 drugs approved
- Carcinoma, Merkel Cell
99 drugs (41 approved, 58 experimental)
- Somatostatinoma
16 drugs (12 approved, 4 experimental)
- Vipoma
10 drugs (8 approved, 2 experimental)
Drugs by status
Phase 3 trials (1)
Phase 2 trials (56)
- gallium-68-dotatate
- atezolizumab
- antineoplaston a10
- antiprimod
- avelumab
- belinostat
- irinotecan
- selinexor
- durvalumab
- fluorouracil
- paclitaxel
- 13c-pyruvate
- nivolumab
- pembrolizumab
- leucovorin
- lurbinectedin
- niraparib
- octreotide
- pen-221
- phenylacetic acid
- ipilimumab
- sunitinib
- carboplatin
- pertuzumab
- temozolomide
- bevacizumab
- everolimus
- topotecan
- trx-818
- dostarlimab
- +26 more
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (105)
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- Advanced Accelerator Applications
- Servier
- Immunomedics
- Merck
- Genentech
- Merck KGaA
- Ipsen
- AIO-Studien-gGmbH
- Novartis
- Callisto Pharmaceuticals
- Karyopharm Therapeutics Inc
- Pharmacia
- Salient Pharmaceuticals Incorporated
- Tarveda Therapeutics
- Cylene Pharmaceuticals
- Eanm Research Ltd
- Otsuka
- Stemcentrx
- TaiRx, Inc.
- Fundación de investigación HM
- The Christie NHS Foundation Trust
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- Fondazione Giovanni Pascale
- Aarhus University
- Barwon Health
- Baylor University
- +75 more
Organization Involved with Phase 1 Indications (16)
- Wyeth
- Blueprint Medicines Corporation
- Medical University Innsbruck
- University of Pisa
- University of Freiburg
- Xencor
- Novella Clinical
- University of Ljubljana
- MannKind Corp
- Jagiellonian University
- University of Alabama, Birmingham
- Erasmus University Rotterdam
- ICON
- Yeshiva University
- NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland
- INRASTES, NCSR Demokritos, Athens, Greece
Organization Involved with Other Experimental Indications (2)